Regeneron Pharmaceuticals, Inc. (REGN)
Automate Your Wheel Strategy on REGN
With Tiblio's Option Bot, you can configure your own wheel strategy including REGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol REGN
- Rev/Share 137.501
- Book/Share 298.764
- PB 2.6897
- Debt/Equity 0.0874
- CurrentRatio 4.0633
- ROIC 0.0918
- MktCap 82996637922.0
- FreeCF/Share 40.0918
- PFCF 19.9785
- PE 18.1887
- Debt/Assets 0.0674
- DivYield 0.0044
- ROE 0.1531
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | REGN | BofA Securities | Underperform | Buy | -- | $860 | Jan. 7, 2026 |
| Downgrade | REGN | Morgan Stanley | Overweight | Equal Weight | -- | $767 | Dec. 3, 2025 |
| Resumed | REGN | Truist | -- | Buy | -- | $798 | Nov. 24, 2025 |
| Initiation | REGN | HSBC Securities | -- | Buy | -- | $255 | Nov. 24, 2025 |
| Initiation | REGN | Scotiabank | -- | Sector Perform | -- | $650 | Nov. 13, 2025 |
| Initiation | REGN | Rothschild & Co Redburn | -- | Buy | -- | $890 | Aug. 14, 2025 |
| Downgrade | REGN | Argus | Buy | Hold | -- | -- | June 30, 2025 |
| Downgrade | REGN | Wells Fargo | Overweight | Equal Weight | -- | $580 | May 30, 2025 |
| Downgrade | REGN | RBC Capital Mkts | Outperform | Sector Perform | -- | $662 | May 30, 2025 |
| Upgrade | REGN | Citigroup | Neutral | Buy | -- | $700 | May 14, 2025 |
News
Regeneron (REGN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Regeneron (REGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Regeneron Pharmaceuticals upgraded by Bank of America on improving fundamentals, 2026 catalysts
Published: January 07, 2026 by: Proactive Investors
Sentiment: Positive
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been upgraded by Bank of America, which raised its rating on the biotechnology company to ‘Buy' from ‘Underperform' and increased its price objective to $860 from $627, citing improving fundamentals across key products and multiple potential catalysts in 2026. Shares of Regeneron traded up 3.5% at about $803 on Wednesday afternoon.
Read More
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
REGN vs. ILMN: Which Stock Is the Better Value Option?
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
REGN vs. ILMN: Which Stock Should Value Investors Buy Now?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
Read More
Regeneron (REGN) Just Flashed Golden Cross Signal: Do You Buy?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Read More
Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv
Published: December 10, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
Published: December 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
Read More
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
Published: December 10, 2025 by: Reuters
Sentiment: Positive
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow transplants, preliminary data from a small mid-stage trial suggest.
Read More
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Published: December 08, 2025 by: Seeking Alpha
Sentiment: Positive
Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin. Moreover, as of September 30, Regeneron had about $2.2 billion remaining under its authorized share repurchase program, underscoring its ongoing efforts to create long-term value for its investors. However, I believe the European Commission's approval of Dupixent for the treatment of chronic spontaneous urticaria on November 25 is even more important.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.
Read More
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.
Read More
Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?
Read More
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
Read More
This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead
Published: November 21, 2025 by: Investopedia
Sentiment: Neutral
November's Wall Street obsession hasn't been AI. It's been healthcare.
Read More
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. ( REGN ) Jefferies London Healthcare Conference 2025 November 17, 2025 10:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Thanks so much, everyone. It's funny.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. ( REGN ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 9:20 AM EST Company Participants Mark Hudson - Investor Relations Executive Isreal Lowy - Senior Vice President of Clinical Development Unit Head & Oncology Justin Holko Conference Call Participants Alexandria Hammond - Wolfe Research, LLC Presentation Alexandria Hammond Wolfe Research, LLC Good morning, everybody. My name is Alex Hammond, and I'm the senior biopharma analyst here at Wolfe Research.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. ( REGN ) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline November 10, 2025 8:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman L. Sirulnik - Senior Vice President of Clinical Development Unit Head & Hematology David Gutstein Conference Call Participants Brian Abrahams - RBC Capital Markets, Research Division Tyler Van Buren - TD Cowen, Research Division David Risinger - Leerink Partners LLC, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Malcolm Hoffman …
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman Marion McCourt - Executive Vice President of Commercial Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Terence Flynn - Morgan Stanley, Research Division Tyler Van …
Read More
Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness
Published: October 28, 2025 by: Benzinga
Sentiment: Positive
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59.
Read More
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
Read More
Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Regeneron (REGN) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
Read More
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.
Read More
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p
Read More
About Regeneron Pharmaceuticals, Inc. (REGN)
- IPO Date 1991-04-02
- Website https://www.regeneron.com
- Industry Biotechnology
- CEO Leonard S. Schleifer
- Employees 15158